DUBLIN–(BUSINESS WIRE)–The “Global
Psychiatry Partnering 2014-2019: Deal Trends, Players and Financials”
report has been added to ResearchAndMarkets.com’s
offering.
Global Psychiatry Partnering 2014 to 2019 provides the full collection
of Psychiatry disease deals signed between the world’s pharmaceutical
and biotechnology companies since 2014.
Most of the deals included within the report occur when a licensee
obtains a right or an option right to license a licensor’s product or
technology. More often these days these deals tend to be multi-component
including both a collaborative R&D and a commercialization of outcomes
element.
The report takes readers through the comprehensive Psychiatry disease
deal trends, key players and top deal values allowing the understanding
of how, why and under what terms companies are currently entering
Psychiatry deals.
The report presents financial deal terms values for Psychiatry deals,
where available listing by overall headline values, upfront payments,
milestones and royalties enabling readers to analyse and benchmark the
value of current deals.
The initial chapters of this report provide an orientation of Psychiatry
dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Psychiatry dealmaking
since 2014 covering trends by year, deal type, stage of development,
technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline
value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Psychiatry deals since 2014.
Deals are listed by headline value. The chapter includes the top 25 most
active Psychiatry dealmakers, together with a full listing of deals to
which they are a party. Where the deal has an agreement contract
published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Psychiatry deals since 2014
where a deal contract is available, providing the user with direct
access to contracts as filed with the SEC regulatory authorities. Each
deal title links via Weblink to an online version of the deal record
contract document, providing easy access to each contract document on
demand.
Chapter 6 provides a comprehensive directory of all Psychiatry
partnering deals by specific Psychiatry target announced since 2014. The
chapter is organized by specific Psychiatry therapeutic target. Each
deal title links via Weblink to an online version of the deal record and
where available, the contract document, providing easy access to each
contract document on demand.
In addition, a comprehensive appendix is provided with each report of
all Psychiatry partnering deals signed and announced since 2014. The
appendices are organized by company A-Z, stage of development at
signing, deal type (collaborative R&D, co-promotion, licensing etc) and
technology type. Each deal title links via Weblink to an online version
of the deal record and where available, the contract document, providing
easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the
trends and activities in Psychiatry partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker
needs to know about partnering in the research, development and
commercialization of Psychiatry technologies and products.
Report Scope
Global Psychiatry Partnering 2014 to 2019 includes:
- Trends in Psychiatry dealmaking in the biopharma industry since 2014
- Analysis of Psychiatry deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Psychiatry deal contract documents
- Comprehensive access to over 3500 Psychiatry deal records
- The leading Psychiatry deals by value since 2014
- Most active Psychiatry dealmakers since 2014
The report includes deals for the following indications: Akathisia,
Anxiety disorder, Generalised anxiety disorder, Panic disorder, Post
traumatic stress disorder, Attention deficit hyperactivity disorder,
Bipolar disorder, Chronic fatigue syndrome, Cognitive impairment,
Delirium, Dementia, Alzheimers, Dementia with lewy bodies, Vascular
dementia, Depression, Dystonia, Eating disorder, Anorexia, Bulimia,
Learning disability, Aspergers, Autism, Mania, Obsessive compulsive
disorder, Personality disorder, Schizophrenia, Sleep disorders,
Insomnia, Narcolepsy, Sleep apnoea, Tardive dyskinesia, Tourettes, plus
other psychiatric indications.
In Global Psychiatry Partnering 2014 to 2019, available deals
and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Key Topics Covered:
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in Psychiatry dealmaking
2.1. Introduction
2.2. Psychiatry partnering over the years
2.3. Psychiatry partnering by deal type
2.4. Psychiatry partnering by industry sector
2.5. Psychiatry partnering by stage of development
2.6. Psychiatry partnering by technology type
2.7. Psychiatry partnering by therapeutic indication
Chapter 3 -Financial deal terms for Psychiatry partnering
3.1. Introduction
3.2. Disclosed financials terms for Psychiatry partnering
3.3. Psychiatry partnering headline values
3.4. Psychiatry deal upfront payments
3.5. Psychiatry deal milestone payments
3.6. Psychiatry royalty rates
Chapter 4 – Leading Psychiatry deals and dealmakers
4.1. Introduction
4.2. Most active in Psychiatry partnering
4.3. List of most active dealmakers in Psychiatry
4.4. Top Psychiatry deals by value
Chapter 5 – Psychiatry contract document directory
5.1. Introduction
5.2. Psychiatry partnering deals where contract document available
Chapter 6 – Psychiatry dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Psychiatry therapeutic target
Appendices
Appendix 1 – Directory of Psychiatry deals by company A-Z 2014 to 2019
Appendix 2 – Directory of Psychiatry deals by deal type 2014 to 2019
Appendix 3 – Directory of Psychiatry deals by stage of development 2014
to 2019
Appendix 4 – Directory of Psychiatry deals by technology type 2014 to
2019
For more information about this report visit https://www.researchandmarkets.com/research/wr3gmn/global_psychiatry?w=4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Mental
Disorders Drugs